Literature DB >> 11553290

Early behavioural changes in scrapie-affected mice and the influence of dapsone.

K Guenther1, R M Deacon, V H Perry, J N Rawlins.   

Abstract

Behavioural testing can reveal effects in scrapie-infected mice long before overt clinical signs appear (Betmouni et al., 1999, Psychobiology, 27, 63-71). These effects may be partly attributable to an early, atypical inflammatory response in the brain (Betmouni et al., 1996, Neuroscience, 74, 1-5). The present study replicated and extended these findings, and examined the effect of chronic treatment with dapsone. This anti-inflammatory compound has been reported to delay disease onset in a rat model of Creutzfeldt-Jakob disease (Manuelidis et al., 1998, Lancet, 352, 456). Although the doses used in the present study were higher than those of Manuelidis et al. (1998), no attenuation of the disease was seen in either behavioural or subsequent histological tests. Burrowing, i.e. displacing food pellets from a tube in the home cage, decreased from around week 12 in scrapie-infected mice, as did consumption of palatable glucose solution. Concurrently, ambulation in an open field increased, as did rearing at around week 17. Spontaneous alternation was impaired around this time. Around 18 weeks, motor performance on an inverted screen, horizontal bar, rotating rod and static rods decreased. Nest construction was impaired at 20 weeks. Overt clinical signs (reduction in mobility, hunched posture, poor coat condition, bladder enlargement) only occurred after week 20, when the mice were prepared for histology. The ME7 scrapie-infected mice thus showed a characteristic complex of neurological and behavioural changes during the course of the disease that were not ameliorated by dapsone. These changes appeared well before clinical signs were prominent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553290     DOI: 10.1046/j.0953-816x.2001.01645.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  42 in total

1.  Measuring motor coordination in mice.

Authors:  Robert M J Deacon
Journal:  J Vis Exp       Date:  2013-05-29       Impact factor: 1.355

2.  Gclc deficiency in mouse CNS causes mitochondrial damage and neurodegeneration.

Authors:  Weiyi Feng; Mariana Rosca; Yuxuan Fan; Yufen Hu; Pingfu Feng; Hyoung-Gon Lee; Vincent M Monnier; Xingjun Fan
Journal:  Hum Mol Genet       Date:  2017-04-01       Impact factor: 6.150

Review 3.  Prion neurodegeneration: starts and stops at the synapse.

Authors:  Giovanna R Mallucci
Journal:  Prion       Date:  2009-10-02       Impact factor: 3.931

4.  Cyclooxygenase-1-dependent prostaglandins mediate susceptibility to systemic inflammation-induced acute cognitive dysfunction.

Authors:  Éadaoin W Griffin; Donal T Skelly; Carol L Murray; Colm Cunningham
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

5.  Toxoplasma gondii infection, from predation to schizophrenia: can animal behaviour help us understand human behaviour?

Authors:  Joanne P Webster; Maya Kaushik; Greg C Bristow; Glenn A McConkey
Journal:  J Exp Biol       Date:  2013-01-01       Impact factor: 3.312

6.  Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice.

Authors:  Fabio Moda; Chiara Vimercati; Ilaria Campagnani; Margherita Ruggerone; Giorgio Giaccone; Michela Morbin; Lorena Zentilin; Mauro Giacca; Ileana Zucca; Giuseppe Legname; Fabrizio Tagliavini
Journal:  Prion       Date:  2012-07-30       Impact factor: 3.931

7.  Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease.

Authors:  Colm Cunningham; Suzanne Campion; Katie Lunnon; Carol L Murray; Jack F C Woods; Robert M J Deacon; J Nicholas P Rawlins; V Hugh Perry
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 8.  The role of microglia in synaptic stripping and synaptic degeneration: a revised perspective.

Authors:  V Hugh Perry; Vincent O'Connor
Journal:  ASN Neuro       Date:  2010-10-14       Impact factor: 4.146

9.  Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Dennisse Gonzalez-Romero; Kristi Green; Giulio Taglialatela; Claudio Soto
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

10.  Plasma membrane invaginations containing clusters of full-length PrPSc are an early form of prion-associated neuropathology in vivo.

Authors:  Susan F Godsave; Holger Wille; Jason Pierson; Stanley B Prusiner; Peter J Peters
Journal:  Neurobiol Aging       Date:  2013-06       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.